We will not update the guideline at this time.
We will transfer the guideline to the static list because:
No evidence was identified that would impact on the current guidance and no major ongoing research has been identified as due to be published in the near future (that is, within the next 3–5 years).
We found 3 new studies through surveillance of this guideline.
This included new evidence on management of underlying pathology that supports current recommendations. Generally, the topic experts thought that an update was not needed.
We did not find any new evidence on individualised assessment at presentation, primary analgesia, reassessment and ongoing management, possible acute complications, non-pharmacological interventions, setting and training, or discharge information.
None of the new evidence considered in surveillance of this guideline was thought to have an effect on current recommendations.
In addition, no major ongoing studies or research due to be published in the next 3–5 years were identified.
One stakeholder has commented that those from socially disadvantaged groups are less likely to speak up about their resultant disadvantages and a 'total care approach' rather than a hospital care approach would reduce this disadvantage. No evidence was identified in relation to this issue from our searches and our recommendations do not exclude these groups.
After considering all the new evidence and views of topic experts, we decided not to update this guideline and to transfer it to the static list.
See how we made the decision for further information.
This page was last updated: 30 August 2016